Charcot-Marie-Tooth Disease Market to Surpass US$ 3,459.1 Million by 2028, Says Coherent Market Insights (CMI)

NEXT STORY
Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer
PREV STORY
Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

author_avatar
NASDAQ Market News

SHIRE RELEASES DATA AT THE WFH CONGRESS 2018 EVALUATING VONVENDI® IN ADULTS WITH VON WILLEBRAND DISEASE DURING AND AFTER SURGERY

P SHIRE RELEASES DATA AT THE WORLD FEDERATION OF HEMOPHILIA CONGRESS 2018 EVALUATING VONVENDI® ...

author_avatar
NASDAQ Market News

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016

DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage ...

author_avatar
NASDAQ Market News